GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » E10

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) E10 : $-5.31 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

EyePoint Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.320. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-5.31 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 5.70% per year. During the past 5 years, the average E10 Growth Rate was -1.10% per year. During the past 10 years, the average E10 Growth Rate was 23.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of EyePoint Pharmaceuticals was 56.90% per year. The lowest was -5.30% per year. And the median was 7.20% per year.

As of today (2024-05-02), EyePoint Pharmaceuticals's current stock price is $19.93. EyePoint Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-5.31. EyePoint Pharmaceuticals's Shiller PE Ratio of today is .


EyePoint Pharmaceuticals E10 Historical Data

The historical data trend for EyePoint Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals E10 Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.62 -6.33 -5.63 -5.67 -5.31

EyePoint Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.67 -5.67 -5.57 -5.47 -5.31

Competitive Comparison of EyePoint Pharmaceuticals's E10

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Shiller PE Ratio falls into.



EyePoint Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EyePoint Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.32/129.4194*129.4194
=-0.320

Current CPI (Dec. 2023) = 129.4194.

EyePoint Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -0.800 99.695 -1.039
201406 -1.400 100.560 -1.802
201409 6.700 100.428 8.634
201412 -1.400 99.070 -1.829
201503 -1.700 99.621 -2.208
201506 -1.700 100.684 -2.185
201509 -1.700 100.392 -2.192
201512 -1.800 99.792 -2.334
201603 -1.500 100.470 -1.932
201606 -1.900 101.688 -2.418
201609 -2.100 101.861 -2.668
201612 -0.020 101.863 -0.025
201703 -1.500 102.862 -1.887
201706 -1.600 103.349 -2.004
201709 -1.500 104.136 -1.864
201712 -1.300 104.011 -1.618
201803 -1.500 105.290 -1.844
201806 -6.200 106.317 -7.547
201809 -4.400 106.507 -5.347
201812 -0.900 105.998 -1.099
201903 -2.000 107.251 -2.413
201906 -1.100 108.070 -1.317
201909 -1.500 108.329 -1.792
201912 -1.000 108.420 -1.194
202003 -1.140 108.902 -1.355
202006 -1.040 108.767 -1.237
202009 -0.300 109.815 -0.354
202012 -1.070 109.897 -1.260
202103 -0.500 111.754 -0.579
202106 -0.350 114.631 -0.395
202109 -0.580 115.734 -0.649
202112 -0.590 117.630 -0.649
202203 -0.560 121.301 -0.597
202206 -0.520 125.017 -0.538
202209 -0.490 125.227 -0.506
202212 -1.160 125.222 -1.199
202303 -0.560 127.348 -0.569
202306 -0.610 128.729 -0.613
202309 -0.330 129.860 -0.329
202312 -0.320 129.419 -0.320

Add all the adjusted EPS together and divide 10 will get our e10.


EyePoint Pharmaceuticals  (NAS:EYPT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


EyePoint Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Executives
Ye Liu director ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Dario A. Paggiarino officer: Chief Medical Officer 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Michael Craig Pine officer: Chief Corp Dev.&Strat. Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Nancy Lurker director, officer: President and CEO PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p. 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Anthony P Adamis director 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension 10 percent owner 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston officer: Chief Financial Officer 124 CHATHAM STREET, CHATHAM NJ 07928
Wendy F Dicicco director
David Scott Jones officer: SVP & Chief Commercial Officer C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
John B. Landis director 1700 KENT AVENUE, WEST LAFAYETTE IN 46906
Jay S. Duker director C/O ELEVEN BIOTHERAPEUTICS, 215 1ST ST. #400, CAMBRIDGE MA 02142
Douglas Evan Godshall director SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Headlines

From GuruFocus